Real-World Immunosuppressant Treatment Patterns for Patients with Lupus Nephritis in the United States.

Jacob N HunnicuttMary Elizabeth GeorgiouLiyuan MaRoger A LevyKerry Gairy

Published in: Rheumatology and therapy (2023)

Around a quarter of patients with LN initiating immunosuppressant therapy switched within 12 months, while a fifth re-initiated induction therapy within 12 months. Use of high corticosteroid doses were observed during 24 months of follow-up. These data suggest that many patients do not respond to existing standard LN therapies.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
stem cells
patient reported outcomes
big data
machine learning
combination therapy
data analysis
bone marrow